BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:afimkibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of afimkibart\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05910528-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:afimkibart: Phase 2 readout est. (NCT05910528)
DESCRIPTION:afimkibart\, phase 2\, Crohn's Disease.\nStudy: Afimkibart (RO7
 790121) for the Treatment of Moderate to Severe Active Crohn's Disease\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05910528
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:afimkibart: Phase 3 readout est. (NCT06589986)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for 
 Induction and Maintenance Therapy in Participants With Moderately to Sever
 ely Active Ulcerative Colitis\nEstimated primary completion: 30 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589986
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137598-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:afimkibart: Phase 2 readout est. (NCT07137598)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to
  Assess the Efficacy and Safety of RO7790121 in Participants With Moderate
  to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot To
 lerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)\nE
 stimated primary completion: 17 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07137598
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665723-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:afimkibart: Phase 1 readout est. (NCT07665723)
DESCRIPTION:afimkibart\, phase 1\, Ulcerative Colitis.\nStudy: An Early-Sta
 ge Study in Multiple Clinics of How Afimkibart May Affect the Body's Proce
 ssing of Medicines That Rely on Cytochrome P450 Enzymes in Participants Wi
 th Ulcerative Colitis\nEstimated primary completion: 31 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07665723
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846683-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07846683)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimk
 ibart in Participants With Moderately to Severely Active Ulcerative Coliti
 s\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07846683
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819891-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819891)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121
 ) in Participants With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06819891
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819878-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819878)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction and Maintenance Therapy With Afimk
 ibart (RO7790121) in Participants With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819878
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158242-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:afimkibart: Phase 3 readout est. (NCT07158242)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to E
 valuate the Pharmacokinetics\, Safety and Efficacy of Afimkibart (RO779012
 1) in Children With Moderately to Severely Active Ulcerative Colitis\nEsti
 mated primary completion: 31 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07158242
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298421-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07298421)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Pharmacokinetics\, Effectiveness and Safety of Afimkibart for Induc
 tion and Maintenance Therapy in Children With Moderately to Severely Activ
 e Crohn's Disease\nEstimated primary completion: 31 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07298421
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223697-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:afimkibart: Phase 2 readout est. (NCT07223697)
DESCRIPTION:afimkibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long Term E
 xtension Study to Evaluate the Safety and Efficacy of Afimkibart (RO779012
 1) in Participants With Atopic Dermatitis\nEstimated primary completion: 1
  March 2033. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/afimkiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7223697
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620392-20@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20330708
DTEND;VALUE=DATE:20330709
SUMMARY:afimkibart: Phase 2 readout est. (NCT07620392)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: An Extensi
 on Study to Assess Long-Term Safety and Efficacy of Afimkibart in Particip
 ants With Rheumatoid Arthritis\nEstimated primary completion: 8 July 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07620392
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
